Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 217 de 371.

Grafa

FDA grants priority review to Merck’s Keytruda combo for muscle-invasive bladder cancer

Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) involving its anti-PD-1 therapy, Keytruda.

Leia mais: FDA grants priority review to Merck’s Keytruda combo for muscle-invasive bladder cancer
Grafa

FDA grants priority review to Pfizer and Astellas for Padcev-Keytruda combo in MIBC

Pfizer (NYSE:PFE) and Astellas announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for the perioperative use of Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab).

Leia mais: FDA grants priority review to Pfizer and Astellas for Padcev-Keytruda combo in MIBC
Grafa

Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial

Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.

Leia mais: Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial
Grafa

Genprex preclinical data shows Reqorsa overcoming resistance in lung cancer

Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company, announced today that its collaborators presented compelling preclinical data for its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Leia mais: Genprex preclinical data shows Reqorsa overcoming resistance in lung cancer
Grafa
Industrials

Stanley Black & Decker affirms 2026 outlook following Section 232 tariff updates

Stanley Black & Decker (NYSE:SWK) announced today that recent adjustments to the Section 232 tariff regime—the federal trade policy governing aluminum and steel imports—are not expected to have a material impact on the company’s full-year 2026 financial guidance.

Leia mais: Stanley Black & Decker affirms 2026 outlook following Section 232 tariff updates